Navigation Links
Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C
Date:8/9/2012

Follow-up research from the Pediatric Study of Hepatitis C (PEDS-C) trial reveals that children treated with peginterferon alpha (pegIFNα) for hepatitis C (HCV) display significant changes in height, weight, body mass index (BMI), and body composition. Results appearing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that most growth-related side effects are reversible with cessation of therapy. However, in many children the height-for-age score had not returned to baseline two years after stopping treatment.

In the U.S. an estimated 240,000 children have the HCV antibody and up to 100,000 have chronic HCV (Jonas, 2002). "While HCV in children is typically mild, some cases do progress to cirrhosis and liver cancer," explains lead author Maureen Jonas, Director of the Center for Childhood Liver Disease and Medical Director of the Liver Transplant Program at Boston Children's Hospital in Massachusetts. "Treatment of HCV with peginterferon and ribavirin is approved for young children and offers the most benefit while liver disease is mild. However, there are concerns about the potential side effects of peginterferon therapy in children, which is the focus of our current study."

Children between the ages of 5 to 18 years with chronic HCV were recruited for the Pediatric Study of Hepatitis C (PEDS-C), a multi-center trial of the safety of pegIFNα with and without ribavirin that took place from December 2004 through May 2006. For the present study, children were followed for an additional two years to determine if height, weight, or BMI were affected by treatment. Subjects were placed into three groups based on duration of pegIFNα therapy at 24, 48 or 72 weeks.

The study group included 107 children with a mean age of 11 years of age; 55% were male, 82% were Caucasian, and all were of normal height, weight, BMI, and body composition at baseline. While on therapy, researchers observed up to a 0.5 unit decrease in height, weight, and BMI z scores (standard deviation scores) in some participants on therapy. In the 48-week treatment group, 33% of children had a greater than 0.5 unit decrement in their height-for-age z score.

Results show that mean height-for-age z scores were slower to rebound than those for weight and BMI. The authors report that after two years following the end of treatment, mean height z scores were lower than baseline in most children who had been treated with peginterferon for 48 or 72 weeks. Physical activity and food intake among the children did not change during the study period.

"Our findings demonstrate significant effects on weight, BMI, and body composition in children treated with pegIFNα that are reversible upon cessation of treatment. A reduction in linear growth persisted even after treatment was discontinued," said Dr. Jonas. "Additional investigation of growth patterns is needed to determine long-term outcomes so that optimal timing of treatment can be determined for children with chronic HCV."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related biology news :

1. University of Tennessee professor releases weight management product
2. Hormone in fruit flies sheds light on diabetes cure, weight-loss drug for humans
3. Infants of overweight mothers grow more slowly
4. Weight-loss clinic drop-out rates are a huge barrier to treating obesity
5. Genetic link to rapid weight gain from antipsychotics discovered
6. Weight gain induced by high-fat diet increases active-period sleep and sleep fragmentation
7. Overweight? Theres a vaccine for that
8. UC Davis study finds that above-normal weight alone does not increase the short-term risk of death
9. Low vitamin D levels linked to weight gain in some older women
10. Eating disorder behaviors and weight concerns are common in women over 50
11. Omega-3 lowers inflammation in overweight older adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/24/2016)... Calif. , Nov. 23, 2016 Cercacor ... endurance athletes and their trainers non-invasively measure ... Index, Pulse Rate, and Respiration Rate in approximately 30 ... enables users easy and immediate access to key data ... part of a training regimen. Hemoglobin ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 02, 2016 , ... In anticipation of AxioMed’s exclusive cleanroom ... company President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. ... Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received ...
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... Nanowear on their recent FDA Class II 510(k) clearance for their flagship medical ... in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other ...
Breaking Biology Technology: